Nyxoah (NYXH) Current Deferred Revenue (2024 - 2026)
Nyxoah (NYXH) posted quarterly Current Deferred Revenue of $1.0 million for Q4 2025, up 737.94% year-over-year from $125025.7 in Q4 2024, and up 101.2% quarter-over-quarter from $520701.5 in Q2 2025.
Nyxoah (NYXH) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Nyxoah's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue rose 737.94% year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (up 737.94% YoY), while the FY2025 annual figure was $1.0 million, up 737.94% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $1.0 million, up from $520701.5 in the prior quarter.
- The five-year high for Current Deferred Revenue was $1.0 million in Q4 2025, with the low at $125025.7 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn |
| 10 | Nyxoah | 90.94 Mn | 90.94 Mn | 5.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Dec 31, 2025 | 1.05 Mn |
| Jun 30, 2025 | 520,701.46 |
| Mar 31, 2025 | 291,371.99 |
| Dec 31, 2024 | 125,025.66 |